Zejula Archives -

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against

GSK takes fight to AZ/Merck & Co with first-line ovarian cancer approval

https://pharmaphorum.com/news/fda-approves-gsks-zejula/

News/ News/ Sales and Marketing

GSK starts 2020 on a high, but warns of tougher times ahead

Phil Taylor coronavirus, financial results, GlaxoSmithKline, Shingrix, Zejula 0 Comment

GlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving

GSK starts 2020 on a high, but warns of tougher times ahead

https://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/

Events/ Events/ Oncology

PARP & DNA Damage Response Inhibitors Summit 2020

jenna.warren@hansonwade.com dna damage response, Oncology, parpi, Zejula

PARP DNA Damage Response Summit DDR Synthetic Lethality

PARP & DNA Damage Response Inhibitors Summit 2020

https://pharmaphorum.com/events/parp-dna-damage-response-inhibitors-summit-2020/

News/ News/ Oncology

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

Phil Taylor AbbVie, AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, Zejula 0 Comment

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

News/ News/ Oncology

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

Phil Taylor AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, PARP inhibitor, Zejula 0 Comment

GlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

News/ News/ Oncology

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

Phil Taylor AstraZeneca, Clovis Oncology, Forxiga, GSK, Lynparza, Oncology, ovarian cancer, PARP inhibitor, Rubraca, type 1 diabetes, Zejula 0 Comment

GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

News/ News/ Oncology/ R&D/ Roche/ Top pharmaceutical companies

Tesaro stock rockets as rumours of Roche takeover abound

Joy Persaud cancer, Clovis Oncology, Oncology, Roche, Rubraca, Tesaro, Zejula 0 Comment

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.

Tesaro stock rockets as rumours of Roche takeover abound

https://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/

Trending

Zejula

Login